Immune-Image

CSA (Coordination and Support Action)

Immune-Image has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 831514. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

01/10/2019 - 30/09/2024 (5 years)

VIEW PARTNERS >

1 STICHTING VUMC Netherlands

2 EBERHARD KARLS UNIVERSITAET TUEBINGEN Germany

3 THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE United Kingdom

4 WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER Germany

5 VRIJE UNIVERSITEIT BRUSSEL Belgium

6 VIB Belgium

7 ACADEMISCH ZIEKENHUIS GRONINGEN Netherlands

8 FUNDACIO PRIVADA INSTITUT D’INVESTIGACIO ONCOLOGICA DE VALL-HEBRON Spain

9 FUNDACIO HOSPITAL UNIVERSITARI VALL D’HEBRON – INSTITUT DE RECERCA Spain

10 COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES France

11 ANTAROS MEDICAL AB Sweden

12 STICHTING LYGATURE Netherlands

13 TTOPSTART BV Netherlands

14 Lawrencium Legal Netherlands

15 EUROPEAN CANCER PATIENT COALITION Belgium

16 F. HOFFMANN-LA ROCHE AG Switzerland

17 BAYER AKTIENGESELLSCHAFT Germany

18 JANSSEN PHARMACEUTICA NV Belgium

19 NOVARTIS PHARMA AG Switzerland

20 PFIZER LIMITED United Kingdom

21 SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT France

22 ASTRAZENECA AB Sweden

23 ImaginAb Inc United States

Why it matters?

The introduction of immunotherapeutic drugs for the treatment of cancer and inflammatory disease, where the drugs encourage the body’s own immune system to attack the disease, have had a significant impact. However, immunotherapies do not work for all patients. Immune-Image Project will develop methods to visualize and study the immune cells involved before, during, and after such treatments allowing selection of the right treatment for the right patient and at the right time. The information obtained about the immune cells and their activity during disease could be used to develop new drugs that might help those patients for which current immunotherapies are ineffective.

“Immunotherapy, a treatment that uses a person’s own immune system to fight cancer was science-fiction a few years ago, now it is reality. Although challenges linked to the therapy are still significant when it comes to accessibility or reimbursement schemes. We need to make sure that all EU citizens have appropriate information, equal access to the newest cancer treatment and that they can afford it.” 

Antonella Cardone, ECPC Director

What ECPC does

ECPC supports communication and dissemination of the Immuno-Image project’s outcomes towards cancer patients and cancer organisations during the duration of the whole project.  This involves conveying information about the trials to confirm safety and to evaluate the clinical potential of novel immunotracers to ECPC cancer patient community and other relevant European patient organisations. ECPC involves multiple patient organisations who would benefit from the project outcomes.